Company intelligence / Profile preview

TIRmed Pharma

Ownership: Private
Development stage: Preclinical

Overview

TIRmed Pharma’s lead program is a novel, non-steroid topical cream for mild to moderate atopic dermatitis. The product candidate, a chemically stabilized single-stranded oligonucleotide, has shown anti-inflammatory and anti-pruritic effects in preclinical models. It acts by modulating immune responses without broad immunosuppression. Proof-of-concept studies have demonstrated local efficacy in animal models; clinical development preparations are ongoing with recent funding secured for further advancement.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Synthetic oligonucleotideSmall molecule (as the compound is a chemically stabilized, single-stranded oligonucleotide)
Industry: Biotech

Partnerships

EU-funded Fight-nCoV project for antiviral nasal spray development

Beyond the preview

Go deeper on TIRmed Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TIRmed Pharma.

Explore the full profile